Cellectis

Share Issue/Capital Change • Nov 12, 2014

PRESS RELEASE

Cellectis received proceeds of €13 Million through the exercise of warrants

November 12, 2014 – Paris (France) – Cellectis (Alternext: ALCLS.PA), a biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CART cells (UCART), announces that it has received €13,237,524 (\$16.5M) through the exercise of 7,354,180 warrants of the 12,195,113 warrants issued in October 2011, which expired on October 28, 2014 (60.3% of the total amount).

An additional 1,470,836 new shares were issued as a result of such exercise.

"We would like to thank our shareholders for their continued support", said Dr. André Choulika, Chairman & CEO of Cellectis. "These additional funds, along with the Company's existing cash and cash equivalents, provide Cellectis with a strong balance sheet that will allow us to continue to execute our strategy focused on developing our therapeutic programs and to advance our product development activities at Cellectis plant sciences."

For further information, please contact:

Cellectis Philippe Valachs / Jennifer Moore Phone: +33 (0)1 81 69 16 00 e-mail: media@cellectis.com

BMC Communications - New York City Brad Miles Phone: 646-513-3125 e-mail: bmiles@bmccommunications.com

About Cellectis

Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CART cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered Tcells. Cellectis capitalizes on its 14 years of expertise in genome engineering - based on its flagship TALEN™ products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies for treating leukemias and solid tumors. Cellectis' adoptive cancer immunotherapy for chronic and acute leukemias is based on allogeneic T-cell chimeric antigen receptor (CAR) technology. CAR technologies are designed to target surface antigens expressed on cells.

Using its life-science-focused, pioneering genome-engineering technologies, Cellectis' goal is to create innovative products in multiple fields and with various target markets.

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives

based on the current expectations and assumptions of the Company's management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements.